Treatment of Hypertension: Is There a Place for Personalization of the Approach in Modern Recommendations?

被引:0
|
作者
Podzolkov, Valery, I [1 ]
Bragina, Anna E. [1 ]
Rodionova, Yulia N. [1 ]
机构
[1] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Trubetskaya Ul 8-2, Moscow 119991, Russia
关键词
arterial hypertension; antihypertensive drugs; clinical guidelines; single-pill combinations of antihypertensive drugs; lisinopril; indapamide; DECREASES BONE-RESORPTION; FIXED-DOSE COMBINATIONS; BLOOD-PRESSURE; INDAPAMIDE SR; METABOLIC SYNDROME; 20; MG; LISINOPRIL; MASS; MICROALBUMINURIA; REGRESSION;
D O I
10.20996/1819-6446-2020-06-05
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The important result of the revision of the European and Russian guidelines for the management of arterial hypertension was a conclusion about the need to use a double combination of antihypertensive drugs as the first stage of antihypertensive therapy. The review presents benefits of combined antihypertensive therapy, confirmed by the results of randomized clinical trials and meta-analysis. There are literature data suggesting one of the first line reasonable combinations is the combination of angiotensin converting enzyme inhibitors (ACEI) and thiazide-like diuretic. The article discusses the benefits of single-pill combinations before free ones, such as increase in patient adherence to long-term treatment, reduction in the cost of the drug and the number of tablets. As an example, a highly effective single-pill combination of one of the most used ACEI, lisinopril and indapamide sustained release, is considered, which has protective activity, vasodilator properties and metabolic neutrality. The article presents the data of the PIFAGOR IV study that indapamide is the most widely used diuretic in Russia, which is characterized by high antihypertensive efficacy, good tolerance, cardioprotective, nephroprotective and osteoprotective properties. The results of large-scale studies, which show the ability of lisinopril to retain target blood pressure level, antiproteinuric and cardioprotective activity, are also presented. This single-pill combination has a long additive effect, contributing to reliable daily monitoring of blood pressure. The authors expressed the opinion that the prescription of highly effective single-pill combinations will contribute to organ protection and reduce the risk of cardiovascular complications development.
引用
收藏
页码:449 / 456
页数:8
相关论文
共 50 条
  • [21] Arterial Hypertension in Diabetes Mellitus: Classical Concepts and Modern Tendencies
    Mamedov, M. N.
    KARDIOLOGIYA, 2013, 53 (01) : 87 - 90
  • [22] How to implement the recommendations of the 2018 ESC/ESH Hypertension Guidelines in a given patient: a step by step approach
    Coca, Antonio
    Domenech, Monica
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (03) : 164 - 170
  • [23] Multidisciplinary Approach in the Treatment of Resistant Hypertension
    Potthoff, S. A.
    Vonend, O.
    CURRENT HYPERTENSION REPORTS, 2017, 19 (01)
  • [24] Clinical approach in treatment of resistant hypertension
    Frank, Jennifer
    Sommerfeld, David
    INTEGRATED BLOOD PRESSURE CONTROL, 2009, 2 : 9 - 23
  • [25] Possibilities of the Use of Moxonidine in the Treatment of Arterial Hypertension in Patients With Metabolic Syndrome and Diabetes
    Minushkina, L. O.
    KARDIOLOGIYA, 2011, 51 (04) : 74 - 78
  • [26] Personalized medicine-a modern approach for the diagnosis and management of hypertension
    Savoia, Carmine
    Volpe, Massimo
    Grassi, Guido
    Borghi, Claudio
    Rosei, Enrico Agabiti
    Touyz, Rhian M.
    CLINICAL SCIENCE, 2017, 131 (22) : 2671 - 2685
  • [27] New Recommendations for the Treatment of Systemic Hypertension and their Potential Implications for Glaucoma Management
    De Moraes, Carlos G.
    Cioffi, George A.
    Weinreb, Robert N.
    Liebmann, Jeffrey M.
    JOURNAL OF GLAUCOMA, 2018, 27 (07) : 567 - 571
  • [28] Diagnosis and treatment of arterial hypertension 2021
    Ott, Christian
    Schmieder, Roland E.
    KIDNEY INTERNATIONAL, 2022, 101 (01) : 36 - 46
  • [29] Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine
    Burnier, Michel
    Pruijm, Menno
    Wuerzner, Gregoire
    RUSSIAN JOURNAL OF CARDIOLOGY, 2010, (02): : 97 - 103
  • [30] Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier, Michel
    Pruijm, Menno
    Wuerzner, Gregoire
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (08) : 981 - 987